Intellia Therapeutics Inc (NTLA)
EBITDA
-$390.38M
TTM · Period ending: · USD
NTLA EBITDA
Latest reported-$390.38Mperiod ending
Latest reported-$390.38Mperiod ending
NTLA TTM EBITDA (-$13.08M → -$390.38M)
TTM EBITDA
High-resolution chart · PNG
NTLA ebitda history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | EBITDA (USD) |
|---|---|
| -390,378,000 | |
| -384,607,000 | |
| -402,409,000 | |
| -433,332,000 | |
| -470,048,000 | |
| -515,643,000 | |
| -508,736,000 | |
| -512,099,000 | |
| -498,929,000 | |
| -476,064,000 | |
| -472,216,000 | |
| -453,897,000 | |
| -445,242,000 | |
| -422,572,000 | |
| -466,614,000 | |
| -434,595,000 | |
| -393,174,000 | |
| -361,505,000 | |
| -261,221,000 | |
| -222,661,000 | |
| -179,303,000 | |
| -143,599,000 | |
| -130,272,000 | |
| -117,663,000 | |
| -115,108,000 | |
| -109,762,000 | |
| -100,764,000 | |
| -92,095,000 | |
| -91,097,000 | |
| -87,497,000 | |
| -86,406,000 | |
| -90,769,000 | |
| -82,907,000 | |
| -75,691,000 | |
| -66,561,000 | |
| -53,096,000 | |
| -45,443,000 | |
| -36,836,000 | |
| -31,055,000 | |
| -25,997,000 | |
| -21,770,000 | |
| -18,426,000 | |
| -13,081,000 | |
| -11,906,500 | |
| -8,701,500 |